Evidence map›Paper›PMID 41452519›Full record

Observational studyJournal of neurology2025

Plasma NFL, GFAP, sTREM2, pTau231, and clinical severity in progressive supranuclear palsy.

Seungmin Lee, Heejung Kim, Ryul Kim, Bora Jin, Seoyeon Kim, Su Hyeon Ha, Jung Hwan Shin, Beomseok Jeon, Han-Joon Kim, Jee-Young Lee

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05579301 (Biomarker Development for Progressive Supranuclear Palsy Through Multi-dimensional SNU-PSP Cohort Database), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05579301 unknown statusnot on this map

Biomarker Development for Progressive Supranuclear Palsy Through Multi-dimensional SNU-PSP Cohort Database

Typeobservational_patient_registrySponsorSeoul National University HospitalRan2021 to 2025Enrolled130ConditionsProgressive Supranuclear Palsy
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Seungmin LeeParkinson and Rare Disease Center, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea.
Heejung KimDepartment of Nuclear Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea.
Ryul KimParkinson and Rare Disease Center, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea.
Bora JinDepartment of Neurology, Dong-A University Hospital, Busan, Korea.
Seoyeon KimDepartment of Neurology, Inha University Hospital, Inha University College of Medicine, Incheon, Korea.
Su Hyeon HaParkinson and Rare Disease Center, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea.
Jung Hwan ShinDepartment of Neurology, Seoul National University College of Medicine, Seoul, South Korea.
Beomseok JeonDepartment of Neurology, Chung-Ang University Health Care System Hyundae Hospital, Namyangju, Korea.
Han-Joon KimDepartment of Neurology, Seoul National University College of Medicine, Seoul, South Korea.
Jee-Young LeeParkinson and Rare Disease Center, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea. wieber04@snu.ac.kr.ORCID http://orcid.org/0000-0002-9120-2075

Funding

Ministry of Education RS-2023-00243810Ministry of Science and ICT, South Korea RS-2022-NR070671
6 · The paper itself

Abstract

objectivesThis study aimed to investigate four plasma markers, pTau231, sTREM2, neurofilament light chain (NFL), and glial fibrillary acidic protein (GFAP), in relation to disease severity in a Korean cohort of progressive supranuclear palsy (PSP).

methodsBaseline data from patients with probable PSP enrolled in the SCANPSP cohort (NCT05579301) were compared with those of age-matched healthy controls (HC). Four plasma markers measured using the Simoa method, clinical findings, and volumetric 3 T MRI were investigated.

resultsThis study included 68 patients with PSP and 30 HC. Group level difference were found in NFL, correlating with the PSP-rating scale (r = 0.48, p = 2.0·10

conclusionThis study demonstrated the feasibility of using four plasma markers simultaneously to determine PSP disease severity. To verify these findings, longitudinal analyses are necessary.

Indexed as

Glial Fibrillary Acidic ProteinMembrane GlycoproteinsNeurofilament ProteinsReceptors, ImmunologicReceptors, ScavengerSupranuclear Palsy, Progressivetau ProteinsAgedBiomarkersCohort StudiesFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedSeverity of Illness IndexBiomarkersGFAP protein, humanGlial Fibrillary Acidic ProteinMembrane Glycoproteinsneurofilament protein LNeurofilament ProteinsReceptors, ImmunologicReceptors, Scavengertau ProteinsTREM2 protein, humanNFLPSPSTREM2

Identifiers

PMID41452519
PMCPMC12743097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.